MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May. The conference presentation schedule is as follows:Deutsche Bank Health Care ConferenceMay 4, 2011 at 11:20 a.m. ETPresented by: Timothy Morris, chief financial officerInterContinental Boston, Boston, MAJMP Securities 10th Annual Research ConferenceMay 9, 2011 at 9:00 a.m. PTPresented by: Dr. Barbara Troupin, senior director, medical affairsThe Ritz-Carlton, San Francisco, CABank of America Merrill Lynch 2011 Health Care ConferenceMay 11, 2011 at 4:20 p.m. PTPresented by: Peter Tam, presidentEncore Hotel, Las Vegas, NVUBS Global Specialty Pharmaceuticals ConferenceMay 25, 2011 at 2:00 p.m. BSTPresented by: Timothy Morris, chief financial officerUBS, One Finsbury Avenue, London, UKA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved